长链非编码RNA PSTAR通过抑制hnRNP K去SUMO化促进p53信号并抑制肝细胞癌
研究通过整合mRNA与lncRNA表达谱的组学分析鉴定肝细胞癌相关lncRNA,发现PSTAR通过结合hnRNP K增强其SUMO化,促进hnRNP K与p53相互作用,诱导p53介导的细胞周期阻滞,抑制肝癌细胞增殖与致瘤性。PSTAR在肝癌组织中下调,低表达预示预后不良,尤其在野生型p53患者中。
要点
- PSTAR在肝癌组织中下调,低表达预示患者预后不良,尤其是野生型p53患者。
- PSTAR通过结合hnRNP K增强其SUMO化,促进hnRNP K与p53相互作用,导致p53积聚与反式激活。
- PSTAR通过诱导p53介导的细胞周期阻滞抑制肝癌细胞增殖与致瘤性。
核心结论
- 本研究揭示了lncRNA PSTAR作为p53通路调节因子在肝细胞癌中的抑癌作用。
研究设计与样本
- 通过整合肝细胞癌组织中mRNA与lncRNA表达谱的组学分析鉴定候选肝癌相关lncRNA。
主要发现
- PSTAR通过结合hnRNP K并增强其SUMO化,强化hnRNP K与p53的相互作用,最终导致p53积聚与反式激活。
- PSTAR通过诱导p53介导的细胞周期阻滞抑制肝癌细胞增殖与致瘤性。
- PSTAR在肝癌组织中下调,低PSTAR表达预示肝癌患者预后不良,尤其是野生型p53患者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To identify hepatocellular carcinoma (HCC)-implicated long noncoding RNAs (lncRNAs), we performed an integrative omics analysis by integrating mRNA and lncRNA expression profiles in HCC tissues. We identified a collection of candidate HCC-implicated lncRNAs. Among them, we demonstrated that an lncRNA, which is named as p53-stabilizing and activating RNA (PSTAR), inhibits HCC cell proliferation and tumorigenicity through inducing p53-mediated cell cycle arrest. We further revealed that PSTAR can bind to heterogeneous nuclear ribonucleoprotein K (hnRNP K) and enhance its SUMOylation and thereby strengthen the interaction between hnRNP K and p53, which ultimately leads to the accumulation and transactivation of p53. PSTAR is down-regulated in HCC tissues, and the low PSTAR expression predicts poor prognosis in patients with HCC, especially those with wild-type p53. Conclusion: This study sheds light on the tumor suppressor role of lncRNA PSTAR, a modulator of the p53 pathway, in HCC.
引用
- Qin G, Tu X, Li H, et al. Long Noncoding RNA p53-Stabilizing and Activating RNA Promotes p53 Signaling by Inhibiting Heterogeneous Nuclear Ribonucleoprotein K deSUMOylation and Suppresses Hepatocellular Carcinoma. Hepatology. 2019. PMID: 31148184. doi:10.1002/hep.30793
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。